S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2027

Conditions
Locally Advanced Gastroesophageal Junction AdenocarcinomaChemotherapy Effect
Interventions
DRUG

Oxaliplatin+S-1

"Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h,d1, q3w~Drug: S-1 S-1: 40\~60mg Bid,d1\~14, q3w"

DRUG

Sinitilimab+oxaliplatin+S-1

"Drug: Sintilimab Sintilimab, recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h,d1, q3w~Drug: S-1 S-1: 40\~60mg Bid,d1\~14, q3w"

Trial Locations (1)

510060

RECRUITING

The sixth affiliated hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

Sun Yat-sen University

OTHER

lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER